These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20190520)

  • 1. [In-silico approaches for fragment-based drug design].
    Takahashi O; Masuda Y; Muroya A; Furuya T
    Yakugaku Zasshi; 2010 Mar; 130(3):349-54. PubMed ID: 20190520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hit triage using efficiency indices after screening of compound libraries in drug discovery.
    Reitz AB; Smith GR; Tounge BA; Reynolds CH
    Curr Top Med Chem; 2009; 9(18):1718-24. PubMed ID: 19929837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Silico Structure-Based Approach for Group Efficiency Estimation in Fragment-Based Drug Design Using Evaluation of Fragment Contributions.
    Shulga DA; Ivanov NN; Palyulin VA
    Molecules; 2022 Mar; 27(6):. PubMed ID: 35335347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fragment-based drug discovery: concept and aim].
    Tanaka D
    Yakugaku Zasshi; 2010 Mar; 130(3):315-23. PubMed ID: 20190516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragments: where are we now?
    Osborne J; Panova S; Rapti M; Urushima T; Jhoti H
    Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACFIS: a web server for fragment-based drug discovery.
    Hao GF; Jiang W; Ye YN; Wu FX; Zhu XL; Guo FB; Yang GF
    Nucleic Acids Res; 2016 Jul; 44(W1):W550-6. PubMed ID: 27150808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing a diverse high-quality library for crystallography-based FBDD screening.
    Tounge BA; Parker MH
    Methods Enzymol; 2011; 493():3-20. PubMed ID: 21371585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lead generation and examples opinion regarding how to follow up hits.
    Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
    Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post processing of protein-compound docking for fragment-based drug discovery (FBDD): in-silico structure-based drug screening and ligand-binding pose prediction.
    Fukunishi Y
    Curr Top Med Chem; 2010; 10(6):680-94. PubMed ID: 20337587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment informatics and computational fragment-based drug design: an overview and update.
    Sheng C; Zhang W
    Med Res Rev; 2013 May; 33(3):554-98. PubMed ID: 22430881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
    Hoffer L; Renaud JP; Horvath D
    J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico fragment-based drug design.
    Konteatis ZD
    Expert Opin Drug Discov; 2010 Nov; 5(11):1047-65. PubMed ID: 22827744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities.
    Huang B; Kang D; Zhan P; Liu X
    Expert Opin Drug Discov; 2015 Dec; 10(12):1271-81. PubMed ID: 26372893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two 'Golden Ratio' indices in fragment-based drug discovery.
    Orita M; Ohno K; Niimi T
    Drug Discov Today; 2009 Mar; 14(5-6):321-8. PubMed ID: 19028598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment databases from screened ligands for drug discovery (FDSL-DD).
    Wilson J; Sokhansanj BA; Chong WC; Chandraghatgi R; Rosen GL; Ji HF
    J Mol Graph Model; 2024 Mar; 127():108669. PubMed ID: 38011826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of Solution NMR in Drug Discovery.
    Shi L; Zhang N
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Size Matters: Diversity for Fragment Library Design.
    Shi Y; von Itzstein M
    Molecules; 2019 Aug; 24(15):. PubMed ID: 31387220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.